Phase II study with etoposide in previously untreated advanced breast cancer

[1]  L. Cirera,et al.  VP16-213 and cyclophosphamide in advanced breast cancer , 1983, Cancer Chemotherapy and Pharmacology.

[2]  P. Alonso,et al.  Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen , 2004, Cancer Chemotherapy and Pharmacology.

[3]  G. Hortobagyi,et al.  Phase II study of VP16-213 (Etoposide) in refractory metastatic breast carcinoma , 2004, Cancer Chemotherapy and Pharmacology.

[4]  J. Hainsworth,et al.  High-dose etoposide (VP-16) in small-cell lung cancer. , 1985, Seminars in oncology.

[5]  G. Anderson,et al.  Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group. , 1985, Seminars in oncology.

[6]  C. Vaughn,et al.  VP-16 and adriamycin in patients with advanced breast cancer. , 1982, American journal of clinical oncology.

[7]  D. V. Van Echo,et al.  Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma. , 1982, American journal of clinical oncology.

[8]  F. Cabanillas,et al.  IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. , 1982, Blood.

[9]  B. Hoogstraten,et al.  Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study. , 1981, Cancer treatment reports.

[10]  W. F. Jungi,et al.  Randomisierte Phase-II-Studie mit VP-16–213 (Etoposide®) in der Behandlung vom fortgeschrittenen Mammakarzinom , 1981 .

[11]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[12]  M. O’connell,et al.  Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer. , 1976, Cancer treatment reports.